Another Symbicort Patent Revoked In EU

Law360, New York (May 6, 2008, 12:00 AM EDT) -- Half a year after a European appellate panel revoked the combination patent for AstraZeneca Plc's blockbuster drug Symbicort's asthma treatment, the same panel has revoked one of two combination patents detailing Symbicort's treatment of emphysema and chronic bronchitis.

The British pharmaceutical giant announced that the European Patent Office Technical Board of Appeal made its final ruling Tuesday against the combination patent, which was the subject of an appeal lodged by two British generics manufacturers.

The revoked patent and one other, against which opposition is pending, together...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.